A polypeptide inhibitor of group B coxsackievirus and its preparation method and application

By designing and applying the polypeptide inhibitor 2B109-150, the HR1 region of Coxsackie virus in Group B was solved, and the problem of lack of specific drugs in the prior art was solved, effective inhibition of the virus was achieved, and new antiviral drugs were provided. Development direction.

CN115093466BActive Publication Date: 2024-11-15HARBIN MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202210635022.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-06
Publication Date
2024-11-15
Estimated Expiration
2042-06-06

AI Technical Summary

Technical Problem

The prior art lacks specific drugs for Group B Coxsackie virus, making it difficult to effectively inhibit virus replication and cytopathy.

Method used

Design and synthesize polypeptide inhibitors based on the HR1 region of Coxsackievirus 2B protein in Group B. The inhibitory effect was verified by Western blotting, microscopy observation and CCK8 experiments. The optimized polypeptide sequence 2B109-150 was selected for exogenous application to inhibit the virus. .

Benefits of technology

The protein expression and cytopathy of Group B coxsackie virus were successfully inhibited, showing significant viral inhibition effects, and providing a potential antiviral drug regimen.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003680004500000041
    Figure BDA0003680004500000041
  • Figure BDA0003680004500000042
    Figure BDA0003680004500000042
  • Figure BDA0003680004500000043
    Figure BDA0003680004500000043
Patent Text Reader

Abstract

The present invention discloses a polypeptide inhibitor of group B coxsackievirus and a preparation method and application thereof. The amino acid sequence of the polypeptide inhibitor is as shown in SEQ ID NO.1‑4. The present invention also proposes the use of the polypeptide inhibitor or group B coxsackievirus 2B protein in the preparation of a drug for inhibiting the replication of group B coxsackievirus. Currently, there is no specific drug for CVB in the clinic. According to the characteristics of the hydrophobic domain of the 2B protein encoded by group B coxsackievirus, the present invention designs three sequences of polypeptide inhibitors. Experimental results show that 2B 109‑150 The polypeptide inhibitor can most effectively inhibit the expression of group B coxsackievirus proteins after endogenous expression in cells. 109‑150 Exogenous inhibitor 2B 109‑150’ The experimental results show that exogenous addition of 2B 109‑150’ Peptide inhibitors can effectively inhibit group B coxsackievirus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a polypeptide inhibitor of group B coxsackievirus and a preparation method and application thereof, and in particular to a polypeptide inhibitor of group B coxsackievirus 2B protein and a preparation method and application thereof. The present invention belongs to the field of medical technology. Background Art

[0002] Group B Coxsackievirus (CVB) is a single positive-stranded small RNA virus. Group B Coxsackievirus belongs to the genus Enterovirus of the family Picornaviridae and has six serotypes (CVB1 to CVB6).

[0003] CVB is the main pathogen of human viral myocarditis and dilated cardiomyopathy. CVB antigen and nucleic acid can be detected in the myocardial tissue of 50% of viral myocarditis and 25% of dilated cardiomyopathy. Attacking mice with CVB can cause viral myocarditis. The CVB genome structure includes the 5'-terminal non-coding region, P1 region, P2 region, P3 region and 3'-terminal non-coding region. The P1 region encodes 4 structural proteins; the P2 and P3 regions are functional protein coding regions, which are divided into 2A, 2B, 2C, 3A, 3B, 3C and 3D functional proteins.

[0004] The 2B protein of CVB virus is a transmembrane protein with 99 amino acid residues, which is composed of an amphipathic HR1 domain and a hydrophobic helical HR2 domain. The 2B protein is localized on the endoplasmic reticulum membrane and the Golgi membrane in the form of a tetramer. The lack of HR1 or HR2 will result in the inability of the 2B protein to form a polymer and insert into the membrane, and it has no biological activity. Therefore, the HR1 and HR2 domains are crucial for the interaction between the 2B protein and the host cell membrane structure.

[0005] Based on the characteristics of the 2B protein domain encoded by group B coxsackievirus, we speculate that the integrity of these hydrophobic structures and their interactions are crucial for the biological function of 2B protein. These findings may provide breakthroughs in the research and development of future antiviral drugs.

[0006] TAT protein is a transactivator of human immunodeficiency virus type I. Recent studies have shown that TAT protein can mediate the entry of exogenous substances such as peptides and genes into cells. It is non-toxic and relatively stable, so it can be directly applied to cells. The core region of the protein transduction domain of TAT protein is composed of 11 amino acid residues. Based on this characteristic, we can administer peptide drugs. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide a polypeptide inhibitor of group B coxsackievirus and application thereof.

[0008] In order to achieve the above object, the present invention adopts the following technical means:

[0009] The inventors of the present invention designed three peptide inhibitor sequences based on the HR1 region of group B coxsackievirus 2B. The amino acid sequences of the peptide inhibitors are shown in any one of SEQ ID NO.1-3. The inhibitory effect of endogenously expressed peptide inhibitors was detected by Western blotting. The results showed that 2B 109-150 The polypeptide inhibitor can most effectively inhibit the expression of group B coxsackievirus protein after endogenous expression in cells. 109-150 Exogenous inhibitor 2B 109-150’ , cytopathic effect was observed under a microscope, 3D protein expression level was detected by Western blotting, and peptide inhibitor 2B was detected by CCK8 experiment 109-150’ The results showed that the exogenous addition of 2B 109-150’ Peptide inhibitors can effectively inhibit group B coxsackievirus.

[0010] Therefore, based on the above research, the present invention proposes a polypeptide inhibitor of group B Coxsackievirus, the amino acid sequence of the polypeptide inhibitor is shown in any one of SEQ ID NO.1-4.

[0011] Preferably, the amino acid sequence of the polypeptide inhibitor is as shown in SEQ ID NO.1 or SEQ ID NO.4.

[0012] The polynucleotide encoding the polypeptide inhibitor, the expression vector containing the polynucleotide, and the host cell containing the expression vector are also within the protection scope of the present invention.

[0013] Furthermore, the present invention also proposes the use of the polypeptide inhibitor or the group B coxsackievirus 2B protein in the preparation of a drug for inhibiting the replication of group B coxsackievirus.

[0014] The use of the polynucleotide in the preparation of a drug for inhibiting the replication of group B coxsackievirus. And

[0015] The expression vector is used in preparing a drug for inhibiting the replication of group B coxsackievirus.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] Currently, there is no specific drug for CVB in clinical practice. According to the characteristics of the hydrophobic domain of the 2B protein encoded by group B Coxsackievirus, the present invention provides three polypeptide inhibitors and successfully constructs a eukaryotic expression plasmid expressing the polypeptide inhibitor. The expression level of 3D protein is detected by Western blotting, and the 2B with the best inhibitory effect is selected. 109-150 The peptides were synthesized, the cytopathic effect was observed under a microscope, the expression level of 3D protein was detected by Western blotting, and the inhibitory effect of peptide inhibitors on group B coxsackievirus was detected by CCK8 experiment. The results showed that 2B 109-150 Peptide inhibitors can effectively inhibit group B coxsackievirus. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 is the plasmid map of pEGFP-C1';

[0019] Figure 2 For sequencing result comparison;

[0020] Figure 3 Western blotting was used to detect the inhibitory effect of expressed proteins containing plasmids with different lengths of 2B sequences;

[0021] Figure 4 To observe the cytopathic effect (CPE) under the microscope, the exogenous addition of 2B 109-150 The inhibitory effect on the virus after

[0022] Figure 5 2B was added for Western blotting detection 109-150 The inhibitory effect on viral proteins;

[0023] Figure 6 For CCK8 assays, exogenous 2B was added 109-150 The inhibitory effect of the inhibitor on CVB3 virus infection. DETAILED DESCRIPTION

[0024] The following examples are provided to facilitate a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified.

[0025] Example 1 Construction of a fusion protein eukaryotic expression plasmid containing a polypeptide inhibitor sequence

[0026] 1. Using pcDNA3.1+ plasmid as the basic plasmid skeleton, amplify the nucleic acid fragment of green fluorescent protein (enhanced green fluorescence protein EGFP) from the pEGFP-N1 plasmid, insert the EGFP fragment into the pcDNA3.1 plasmid, and construct the pEGFP-C1' plasmid. The EGFP reading frame is located downstream of the CMV promoter. The TAA stop codon has been knocked out of the EGFP reading frame, and the two ends are connected by NheⅠ and HindⅢ restriction endonucleases respectively. A flexible connection (5'-GGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCG-3') is connected downstream of the EGFP reading frame to ensure the relative independence of the spatial structure of the proteins on both sides. The plasmid map is shown in the figure below. Figure 1 shown.

[0027] 2. Three pairs of primers were designed to amplify the coding sequences of three polypeptide inhibitors of different sizes. Restriction endonuclease nucleic acid sites HindⅢ (AAGCTT) and XbaⅠ (TCTAGA) were introduced at the 5' end of the upstream and downstream primers for subsequent vector connection. The primer sequences are shown in Table 1. The target fragments were obtained by complete overlap-PCR. The amino acid sequence encoded by the target fragments is shown in Table 2, and the nucleotide sequence is shown in Table 3. pEGFP-C1' was treated with restriction endonucleases HindⅢ and XbaⅠ for double digestion. The digested products were purified and recovered by gel recovery kit. The target fragments were connected to the vector, the connected products were transformed, and the expression 2B was obtained. 109-150 , 2B 109-162 , 2B 109-189 The sequence comparison results of three fusion protein eukaryotic expression plasmids are as follows Figure 2 As shown, they were named pEGFP-C1'-2B 109-150 , pEGFP-C1'-2B 109-162 , pEGFP-C1'-2B 109-189 .

[0028] Table 1 Primer sequences of group B coxsackievirus 2B protein inhibitors

[0029]

[0030] Table 2 Amino acid sequences of peptide inhibitors of group B coxsackievirus

[0031]

[0032] Table 3 Nucleotide sequences encoding group B coxsackievirus polypeptide inhibitors

[0033]

[0034]

[0035] At the same time, the present invention also constructs eukaryotic expression plasmids expressing the full-length fusion proteins of 2B and 2C, which are named pEGFP-C1'-2B and pEGFP-C1'-2C.

[0036] Example 2 Inhibitory effect of fusion protein eukaryotic expression plasmid containing polypeptide inhibitor sequence

[0037] Western blotting experiment:

[0038] First, extract the fusion protein eukaryotic expression plasmid pEGFP-C1'-2B containing the peptide inhibitor sequence 109-150 , pEGFP-C1'-2B 109-162 , pEGFP-C1'-2B 109-189 , pEGFP-C1'-2B and pEGFP-C1'-2C for eukaryotic cell transfection experiments:

[0039] Vero cells were plated in 6-well plates and cultured in a cell culture incubator at 37°C and 5% CO2. When the cell growth area was 60%-70% of the bottom area of ​​the well plate, 1 μg of fusion protein expression plasmid was transfected into the Vero cells. The transfection reagent used was NEOFECT TM DNA transfection reagent, transfection operation refers to the reagent manual. 24h after transfection, add DMEM containing virus (MOI = 0.1), and change to cell culture medium with serum 1h later. After observing the cytopathic effect, centrifuge and collect the cell pellet, then add lysis solution to lyse the cells for 30 minutes, extract protein, determine the protein concentration and use 10% SDS-PAGE. Western blotting was performed with anti-3D and EGFP antibodies to detect the inhibitory effect of the expressed protein on the virus.

[0040] result:

[0041] Figure 3 Western blotting was used to detect the inhibitory effect of expressed proteins containing plasmids with different lengths of 2B sequences. 109-150 The inhibitory effect was the most significant, so it was selected as the exogenous peptide inhibitor for the next experiment.

[0042] Example 32B 109-150’ Synthesis of peptide inhibitors and their inhibitory effects on viruses

[0043] 1.2B 109-150’ Synthesis of peptide inhibitors

[0044] According to the research results of Example 2, the inventors of the present invention synthesized an exogenous 2B inhibitor, the amino acid sequence of which is shown in Table 4.

[0045] Table 4 Amino acid sequences of exogenous 2B inhibitors

[0046]

[0047] 2.2B 109-150’ The inhibitory effect of peptide inhibitors on viruses

[0048] (1) CPE experiment:

[0049] Vero cells were plated in 6-well plates and cultured in a cell culture incubator at 37°C and 5% CO2. When the cell growth area was 60%-70% of the bottom area of ​​the well plate, different concentrations of peptide inhibitor 2B were added. 109-150’ 4 hours later, DMEM containing CVB3 virus (MOI=0.1) was added, and 1 hour later, the medium was changed to cell culture medium with serum, and the culture was continued to observe the cytopathic effect.

[0050] result:

[0051] Figure 4 The cytopathic effect (CPE) was observed under a microscope to detect exogenously added peptide inhibitor 2B 109-150’ The results show that 2B 109-150’ It has a significant inhibitory effect on viruses.

[0052] (2) Western blotting experiment:

[0053] After observing the cytopathic effect, the cell pellet was collected by centrifugation, and then the cells were lysed for 30 minutes by adding lysis buffer, and the protein was extracted. After the protein concentration was determined, 10% SDS-PAGE was used. Western blotting was performed with anti-VP1 and 3D antibodies to detect exogenous addition of 2B 109-150’ The inhibitory effect on the virus.

[0054] result:

[0055] Figure 5 Western blotting was performed using anti-VP1 and 3D antibodies to detect 2B 109-150’ The inhibitory effect of peptide inhibitors on viruses. From this result, it can be seen that 2B 109-150’ It has a significant inhibitory effect on viruses.

[0056] (3) CCK8 experiment:

[0057] Vero cells were plated in a 96-well plate, with 100ul of cell culture medium per well, and cultured in a cell culture incubator at 37°C and 5% CO2. When the cell growth area was 50% of the bottom area of ​​the well plate, different concentrations of peptide inhibitor 2B were added. 109-150’ , after 4 hours, add DMEM containing CVB3 virus (MOI=0.1), and after 1 hour, change to cell culture medium with serum. After continuing to culture and observing cytopathic effect, add 10ul CCK8 and culture for 1-2 hours. After the color turns orange-red, measure the absorbance at 450nm.

[0058] result:

[0059] Figure 6 The CCK8 assay detects exogenously added 2B 109-150’ The inhibitory effect on CVB3 virus infection. 109-150’ It has a significant inhibitory effect on viruses. Sequence Listing <110> Harbin Medical University <120> A polypeptide inhibitor of group B coxsackievirus and its preparation method and application <141> 2022-06-06 <160> 4 <170> SIPOSequenceListing 1.0 <210> 1 <211> 14 <212> PRT <213> artificial sequence <400> 1 Ser Ile Leu Glu Lys Ser Leu Lys Ala Leu Val Lys Ile Ile 1 5 10 <210> 2 <211> 18 <212> PRT <213> artificial sequence <400> 2 Ser Ile Leu Glu Lys Ser Leu Lys Ala Leu Val Lys Ile Ile Ser Ala 1 5 10 15 Leu Val <210> 3 <211> 27 <212> PRT <213> artificial sequence <400> 3 Ser Ile Leu Glu Lys Ser Leu Lys Ala Leu Val Lys Ile Ile Ser Ala 1 5 10 15 Leu Val Ile Val Ala Arg Asn His Asp Asp Leu 20 25 <210> 4 <211> 28 <212> PRT <213> artificial sequence <400> 4 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Ser Gly Ser Ile 1 5 10 15 Leu Glu Lys Ser Leu Lys Ala Leu Val Lys Ile Ile 20 25

Claims

1. A polypeptide inhibitor of group B coxsackievirus (CVB), characterized in that The amino acid sequence of the polypeptide inhibitor is shown in any one of SEQ ID NO. 1, 2 or 4.

2. The polypeptide inhibitor according to claim 1, characterized in that The amino acid sequence of the polypeptide inhibitor is shown in SEQ ID NO.1 or SEQ ID NO.

4.

3. A polynucleotide encoding the polypeptide inhibitor according to claim 1, characterized in that: The polynucleotide encodes the amino acid sequence shown in SEQ ID NO.1 or 2.

4. An expression vector, characterized in that: Contains the polynucleotide according to claim 3.

5. The expression vector according to claim 4, characterized in that The expression vector is a eukaryotic expression vector.

6. A host cell, characterized in that Containing the expression vector according to claim 4 or 5.

7. Use of the polypeptide inhibitor according to claim 1 or 2 in the preparation of a drug for inhibiting the replication of group B coxsackievirus.

8. Use of the polynucleotide according to claim 3 in the preparation of a drug for inhibiting the replication of group B coxsackievirus.

9. Use of the expression vector according to claim 4 or 5 in the preparation of a drug for inhibiting the replication of group B coxsackievirus.

Citation Information

Patent Citations

  • Protein containing 36-83 amino acid motifs in Coxsackie B3virus 2B protein and application thereof

    CN102512662A

  • Expression system of heterologous gene using attenuated coxsackievirus genome

    KR1020090024387A

  • Detection of an antibody against a pathogen

    WO2017132550A1